COVID-19大流行相关的抗生素耐药性:系统综述与Meta分析
该系统综述与Meta分析检索了世卫组织COVID-19研究数据库及引文追踪,纳入28项研究(23项可合并),评估COVID-19大流行对医疗环境中抗菌药物耐药性的影响。大流行与耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌的发病率密度或比例变化无关,革兰阴性菌耐药呈非统计学显著的升高;未报告增强感染防控和/或抗菌药物管理项目与革兰阴性菌耐药升高相关(风险比1.11,95%CI 1.03-1.20),但亚组差异检验无统计学意义(p 0.40)。
要点
- 大流行与MRSA和VRE的发病率密度(IRR 0.99,95%CI 0.67-1.47)或比例(RR 0.91,95%CI 0.55-1.49)变化无关。
- 革兰阴性菌耐药呈非统计学显著升高(IRR 1.64,95%CI 0.92-2.92;RR 1.08,95%CI 0.91-1.29)。
- 未报告增强感染防控和/或抗菌药物管理项目与革兰阴性菌耐药升高相关(RR 1.11,95%CI 1.03-1.20),但亚组差异无统计学意义(p 0.40)。
核心结论
- COVID-19大流行可能加速了抗菌药物耐药性的出现和传播,尤其是医院环境中的革兰阴性菌。
- 但研究间采用的耐药指标和报告的耐药率存在相当大的异质性。
- 这些发现强调在COVID-19大流行背景下需要加强感染预防、抗菌药物管理和耐药监测。
研究设计与样本
- 系统综述与Meta分析,检索2021年12月世卫组织COVID-19研究数据库并向前引文追踪至2022年6月。
- 纳入评估COVID-19对任何人群抗菌药物耐药性影响的研究,提取影响因素并记录是否报告增强感染防控和/或抗菌药物管理项目。
- 共筛选6036项研究,纳入28项,其中23项提供足够数据进行Meta分析;多数研究聚焦医院环境(n=25,89%)。
- 对革兰阴性菌和革兰阳性菌分别进行随机效应Meta分析。
主要发现
- COVID-19大流行与耐甲氧西林金黄色葡萄球菌或耐万古霉素肠球菌的发病率密度变化无关(发病率比0.99,95%CI 0.67-1.47),与比例变化也无关(风险比0.91,95%CI 0.55-1.49)。
- 耐药革兰阴性菌(产超广谱β-内酰胺酶、耐碳青霉烯肠杆菌目、耐碳青霉烯或多重耐药或耐碳青霉烯铜绿假单胞菌或鲍曼不动杆菌)呈非统计学显著升高(发病率比1.64,95%CI 0.92-2.92;风险比1.08,95%CI 0.91-1.29)。
- 未报告增强感染防控和/或抗菌药物管理项目与革兰阴性菌耐药升高相关(风险比1.11,95%CI 1.03-1.20)。
- 亚组差异检验显示有无这些项目之间无统计学显著差异(p 0.40)。
关键数值与推荐
- 耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌:发病率比0.99(95%CI 0.67-1.47),风险比0.91(95%CI 0.55-1.49)。
- 耐药革兰阴性菌:发病率比1.64(95%CI 0.92-2.92),风险比1.08(95%CI 0.91-1.29)。
- 未报告增强感染防控和/或抗菌药物管理项目与革兰阴性菌耐药:风险比1.11(95%CI 1.03-1.20)。
- 亚组差异检验:p 0.40。
临床怎么用
- 原文结论强调在COVID-19大流行背景下需要加强感染预防、抗菌药物管理和耐药监测。
局限性
- 研究间采用的抗菌药物耐药指标和报告的耐药率存在相当大的异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 and antimicrobial resistance (AMR) are two intersecting global public health crises. OBJECTIVE: We aimed to describe the impact of the COVID-19 pandemic on AMR across health care settings. DATA SOURCE: A search was conducted in December 2021 in WHO COVID-19 Research Database with forward citation searching up to June 2022. STUDY ELIGIBILITY: Studies evaluating the impact of COVID-19 on AMR in any population were included and influencing factors were extracted. Reporting of enhanced infection prevention and control and/or antimicrobial stewardship programs was noted. METHODS: Pooling was done separately for Gram-negative and Gram-positive organisms. Random-effects meta-analysis was performed. RESULTS: Of 6036 studies screened, 28 were included and 23 provided sufficient data for meta-analysis. The majority of studies focused on hospital settings (n = 25, 89%). The COVID-19 pandemic was not associated with a change in the incidence density (incidence rate ratio 0.99, 95% CI: 0.67-1.47) or proportion (risk ratio 0.91, 95% CI: 0.55-1.49) of methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci cases. A non-statistically significant increase was noted for resistant Gram-negative organisms (i.e. extended-spectrum beta-lactamase, carbapenem-resistant Enterobacterales, carbapenem or multi-drug resistant or carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii, incidence rate ratio 1.64, 95% CI: 0.92-2.92; risk ratio 1.08, 95% CI: 0.91-1.29). The absence of reported enhanced infection prevention and control and/or antimicrobial stewardship programs initiatives was associated with an increase in gram-negative AMR (risk ratio 1.11, 95% CI: 1.03-1.20). However, a test for subgroup differences showed no statistically significant difference between the presence and absence of these initiatives (p 0.40). CONCLUSION: The COVID-19 pandemic may have hastened the emergence and transmission of AMR, particularly for Gram-negative organisms in hospital settings. But there is considerable heterogeneity in both the AMR metrics used and the rate of resistance reported across studies. These findings reinforce the need for strengthened infection prevention, antimicrobial stewardship, and AMR surveillance in the context of the COVID-19 pandemic.
引用
- Langford BJ, Soucy JR, Leung V, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. Clin Microbiol Infect. 2022. PMID: 36509377. doi:10.1016/j.cmi.2022.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。